Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03921294 · ClinicalTrials.gov registry record · Phase 4
HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor
A Phase 4 study, sponsored by Indiana Hemophilia &Thrombosis Center.
- Terminated
- Registry status
- Phase 4
- Development phase
- 1
- Enrollment target
NCT03921294: Clinical Trial Phase 4 study, sponsored by Indiana Hemophilia &Thrombosis Center.
NCT03921294 is a Phase 4 study that was terminated before completion, run by Indiana Hemophilia &Thrombosis Center. The registered enrollment target is 1 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03921294, a Phase 4 study, was terminated before completion, sponsored by Indiana Hemophilia &Thrombosis Center.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a single arm, phase 4, prospective, open-label, United States single-center study to assess the hemostatic efficacy and safety of Hemlibra (emicizumab) for hemostatic control of hemophilia A patients (baseline FVIII level \<40%) with and without inhibitors with hemophilic pseudotumors; secondary outcomes will assess changes in quality of life and activity level in treated patients.
Primary Outcome
Maintenance or increase of hemoglobin (g/dl) from participants' baseline level based on serial blood tests.
Interventions
- DRUG Emicizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-05-15 |
| Est. Completion | 2022-03-16 |
| Phase | Phase 4 |
Why NCT03921294 stopped before completion
NCT03921294 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (100% lower).
The record links to 0 conditions, and to 1 intervention - of which Emicizumab is the first listed.
NCT03921294 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03921294 about?
NCT03921294 is a clinical study titled "HemLibra Prophylaxis in Patients With Hemophilic Pseudotumor". This is a single arm, phase 4, prospective, open-label, United States single-center study to assess the hemostatic efficacy and safety of Hemlibra (emicizumab) for hemostatic control of hemophilia A patients (baseline FVIII level \<40%) with and without inhibitors with hemophilic pseudotumors; secon...
What is the current status of trial NCT03921294?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 1 participants. The study started on 2019-05-15. Estimated completion is 2022-03-16.
What interventions are being tested in trial NCT03921294?
The interventions under investigation include: Emicizumab (DRUG).
Who is sponsoring clinical trial NCT03921294?
This trial is sponsored by Indiana Hemophilia &Thrombosis Center, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03921294's enrollment target sits among peer trials
1 2000th of 2000 the lowest of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI